Research programme: gastrointestinal disorder therapies - Albireo AB
Latest Information Update: 18 Dec 2014
At a glance
- Originator AstraZeneca
- Developer Albireo AB
- Class
- Mechanism of Action Sodium-bile acid cotransporter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Dyspepsia; Gastrointestinal disorders; Inflammatory bowel diseases
Most Recent Events
- 01 Dec 2014 Discontinued - Preclinical for Inflammatory bowel disease, Gastrointestinal disorders and Dyspepsia in Europe (unspecified route)
- 08 Oct 2008 Preclinical trials in Dyspepsia in Europe (unspecified route)
- 08 Oct 2008 Preclinical trials in Gastrointestinal disorders in Europe (unspecified route)